Recently, an open-label prospective RCT compared a combination of metformin (1000 mg twice daily) and canagliflozin (100 mg daily), an SGLT2 inhibitor, with metformin alone for a 3-month treatment in 51 overweight or obese non-diabetic PCOS women aged 18–40 years [203]. The gene discussed is SLC5A2; the disease is polycystic ovary syndrome.